Company Overview
EMvision Medical Devices Ltd, listed on the ASX under the ticker symbol EMV, has been a subject of interest for several years. The company was established in 2017 and made its debut on the Australian Securities Exchange in 2018. Its primary goal is to revolutionise stroke care by introducing innovative solutions that can significantly improve patient outcomes globally.
The lead product currently in development is a portable, cost-effective, and non-ionising brain scanner. This device is designed to quickly determine the presence of suspected strokes and identify their type, offering valuable insights to medical professionals. The scanner is a hospital and cart-based device that can be easily moved around, making it suitable for use in Stroke Centres, Intensive Care Units, and Emergency Departments. It is known as “emu” and represents a significant advancement in the field of neurodiagnostics.
Fresh Clinical Trial Update
A recent report from Bell Potter has provided an updated view on EMvision following a key clinical trial update. According to the report, the company is expanding its main clinical trial to include the detection of both bleeding strokes (haemorrhagic) and blocked-vessel strokes (ischaemic). This expansion is crucial because while only about 13% of strokes are bleeding strokes, approximately 87% are ischaemic.
By incorporating the ability to detect ischaemic strokes, EMvision aims to make its device useful for a broader range of patients. This additional indication is expected to add a relatively modest amount of time to the Pivotal trial’s timeline, with enrolment now anticipated to be completed in late CY26 or early CY27.
Currently, 125 patients have been enrolled across multiple sites, with a target of 300 patients. Including the ischaemia detection endpoint in the current Pivotal Trial allows the company to leverage the same patient cohorts, infrastructure, and regulatory pathway, potentially saving up to two years and several million dollars in trial costs compared to funding a standalone trial later.
Steady Progress
Despite the extended trial timeline, adding ischaemia as a primary endpoint appears to be a strategic move from a cost, timeline, and commercial value perspective. Bell Potter has retained its buy recommendation on this ASX small-cap, along with its price target of $3.15. From yesterday’s closing price of $1.89, this indicates an upside potential of approximately 67%.
EMV continues to make steady progress in its Pivotal Trial and other studies. The post-readout timeline is expected to be in 3QFY27, followed by an FDA decision on the De Novo application in 1H28.
Investment Considerations
Before considering an investment in EMVision Medical Devices shares, it is essential to evaluate various factors. While the company has shown promising developments, investors should also consider the recommendations of experienced financial analysts. For instance, Motley Fool investing expert Scott Phillips recently highlighted what he believes are the 5 best stocks for investors to buy right now, although EMVision Medical Devices was not among them.
Investors should also take into account the general investment advice provided in this article, which is under AFSL 400691. The information contained here is intended for general guidance and should not be considered as specific investment advice.
For more information on related topics, readers may explore additional articles such as:
- Is this ASX gold stock a buy, hold or sell after its quarterly results?
- Is this ASX energy stock a buy, hold or sell following quarterly results?
- Here’s why Morgans just upgraded Woolworths shares
- Bell Potter says this ASX real estate stock could rise 33%
- Top 10 ASX shares bought and sold in April
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended EMVision Medical Devices. However, the Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only. Authorised by Scott Phillips.
